March 27, 2026

FDA Approval Advances Basal Insulin

Weekly dosing reduces injection frequency vs daily regimens, with phase 3 data supporting efficacy and class-consistent safety.

Conexiant

March 26, 2026

Excess Fat Linked to Weaker Bones in Autoimmune Diabetes

Pilot study finds adiposity impairs femur strength and geometry while leaving bone mineral density unchanged, highlighting limits of standard fracture risk assessment.

Conexiant

March 26, 2026

GLP-1 Drugs Examined in Psychiatric Outcomes

Researchers evaluate mental health trajectories with antidiabetic therapies in patients with depression or anxiety.

Conexiant

March 26, 2026

Type 1 Diabetes Shapes Pregnancy, Motherhood Experiences

Qualitative study highlights concerns about heredity, information gaps, and balancing diabetes management with parenting

Conexiant

March 26, 2026

Ultrasound Models Estimate Whole-Body Muscle Mass

New equations incorporating cross-sectional area improve estimation accuracy.

Conexiant

March 24, 2026

Mammography AI Spots Vascular Signals

Routine breast imaging offers opportunity for cardiovascular risk assessment.

Conexiant

March 24, 2026

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.

Conexiant

March 23, 2026

Metabolic Acidosis Care Limited in Chronic Kidney Disease

Low testing rates may contribute to underdiagnosis and undertreatment in Japan

Conexiant

March 20, 2026

Healthy Lifestyle Lowers Cardiometabolic Risk in Hypertension

Sustained and improved behaviors following diagnosis tied to lower cardiometabolic risk, highlighting an underused opportunity in care

Conexiant

March 19, 2026

Wegovy HD Secures FDA Approval

Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials.

Conexiant